These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555 [TBL] [Abstract][Full Text] [Related]
8. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988 [TBL] [Abstract][Full Text] [Related]
9. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia. Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G; Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409 [TBL] [Abstract][Full Text] [Related]
10. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442 [TBL] [Abstract][Full Text] [Related]
11. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience. Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355 [TBL] [Abstract][Full Text] [Related]
12. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Shimony S; Stone RM; Stahl M Curr Opin Hematol; 2022 Mar; 29(2):63-73. PubMed ID: 34966123 [TBL] [Abstract][Full Text] [Related]
13. Venetoclax in acute myeloid leukemia - current and future directions. Lachowiez C; DiNardo CD; Konopleva M Leuk Lymphoma; 2020 Jun; 61(6):1313-1322. PubMed ID: 32031033 [TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Kadia TM; Reville PK; Wang X; Rausch CR; Borthakur G; Pemmaraju N; Daver NG; DiNardo CD; Sasaki K; Issa GC; Ohanian M; Montalban-Bravo G; Short NJ; Jain N; Ferrajoli A; Bhalla KN; Jabbour E; Takahashi K; Malla R; Quagliato K; Kanagal-Shamanna R; Popat UR; Andreeff M; Garcia-Manero G; Konopleva MY; Ravandi F; Kantarjian HM J Clin Oncol; 2022 Nov; 40(33):3848-3857. PubMed ID: 35704787 [TBL] [Abstract][Full Text] [Related]
15. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352 [TBL] [Abstract][Full Text] [Related]
16. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400 [TBL] [Abstract][Full Text] [Related]
17. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer? Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064 [TBL] [Abstract][Full Text] [Related]
18. Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America. Gómez-De León A; Demichelis-Gómez R; Pinedo-Rodríguez A; Enriquez-Vera D; Flores-Jiménez JA; Ceballos-López AA; Rodríguez-Mejorada M; Herrera Riojas MA; Ovilla-Martínez R; Báez-Islas P; Cota-Rangel X; Neme-Yunes Y; Inclán-Alarcón S; López-Flores NJ; Colunga-Pedraza PR; Rodríguez-Zúñiga AC; Gómez-Almaguer D Hematology; 2022 Dec; 27(1):249-257. PubMed ID: 35192778 [No Abstract] [Full Text] [Related]
19. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Ball BJ; Arslan S; Koller P; Ngo D; Afkhami M; Salhotra A; Al-Malki M; Aribi A; Ali H; Sandhu K; Otoukesh S; Amanam I; Pourhassan H; Artz A; Curtin P; Stein A; Nakamura R; Marcucci G; Smith E; Pullarkat V; Aldoss I Leuk Lymphoma; 2022 Dec; 63(13):3232-3236. PubMed ID: 36089918 [No Abstract] [Full Text] [Related]
20. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia. Maiti A; Konopleva MY Cancer J; 2022 Jan-Feb 01; 28(1):2-13. PubMed ID: 35072368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]